Advanced

A population-based study on the first forty-eight breast cancer patients receiving trastuzumab (Herceptin (R)) on a named patient basis in Sweden

Andersson, J; Linderholm, B; Greim, G; Lindh, B; Lindman, H; Tennvall, Jan LU ; Tennvall-Nittby, L; Pettersson-Skold, D; Sverrisdottir, A and Soderberg, M, et al. (2002) In Acta Oncologica 41(3). p.276-281
Abstract
Several studies have presented data on the efficacy and tolerability of trastuzumab within clinical trials. As a minority of patients is included in these trials, we undertook this retrospective study to describe trastuzumab therapy in clinical routine and its tolerability. We reviewed the medical records of the first 48 patients in Sweden who received treatment with trastuzumab on a named patient basis with (n = 29) and without (n = 19) chemotherapy. Forty-six patients had metastatic disease and had failed to respond to several prior regimens before starting antibody treatment. Two patients had locally advanced breast cancer failing on given neoadjuvant therapy. Patients with breast cancers with strong (3+) c-erbB-2 overexpression tended... (More)
Several studies have presented data on the efficacy and tolerability of trastuzumab within clinical trials. As a minority of patients is included in these trials, we undertook this retrospective study to describe trastuzumab therapy in clinical routine and its tolerability. We reviewed the medical records of the first 48 patients in Sweden who received treatment with trastuzumab on a named patient basis with (n = 29) and without (n = 19) chemotherapy. Forty-six patients had metastatic disease and had failed to respond to several prior regimens before starting antibody treatment. Two patients had locally advanced breast cancer failing on given neoadjuvant therapy. Patients with breast cancers with strong (3+) c-erbB-2 overexpression tended to have an improved survival from start of trastuzumab treatment versus those with a moderate (2+) overexpression (p=0.09). Adverse events were registered in 22 patients (46%). The most common and acute side effects were fever and chills (7 patients, 15%). The toxicity seemed reasonable but two patients (4%) suffered serious cardiac events, both of them having received previous treatment with antracyclines. (Less)
Please use this url to cite or link to this publication:
author
, et al. (More)
(Less)
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Acta Oncologica
volume
41
issue
3
pages
276 - 281
publisher
Taylor & Francis
external identifiers
  • wos:000177014000007
  • pmid:12195747
  • scopus:18444364495
ISSN
1651-226X
DOI
10.1080/02841860260088827
language
English
LU publication?
yes
id
6e0a7f6e-151d-4835-8e55-7e7adece9ba8 (old id 332858)
date added to LUP
2007-08-02 11:35:36
date last changed
2017-01-01 06:42:22
@article{6e0a7f6e-151d-4835-8e55-7e7adece9ba8,
  abstract     = {Several studies have presented data on the efficacy and tolerability of trastuzumab within clinical trials. As a minority of patients is included in these trials, we undertook this retrospective study to describe trastuzumab therapy in clinical routine and its tolerability. We reviewed the medical records of the first 48 patients in Sweden who received treatment with trastuzumab on a named patient basis with (n = 29) and without (n = 19) chemotherapy. Forty-six patients had metastatic disease and had failed to respond to several prior regimens before starting antibody treatment. Two patients had locally advanced breast cancer failing on given neoadjuvant therapy. Patients with breast cancers with strong (3+) c-erbB-2 overexpression tended to have an improved survival from start of trastuzumab treatment versus those with a moderate (2+) overexpression (p=0.09). Adverse events were registered in 22 patients (46%). The most common and acute side effects were fever and chills (7 patients, 15%). The toxicity seemed reasonable but two patients (4%) suffered serious cardiac events, both of them having received previous treatment with antracyclines.},
  author       = {Andersson, J and Linderholm, B and Greim, G and Lindh, B and Lindman, H and Tennvall, Jan and Tennvall-Nittby, L and Pettersson-Skold, D and Sverrisdottir, A and Soderberg, M and Klaar, S and Bergh, J},
  issn         = {1651-226X},
  language     = {eng},
  number       = {3},
  pages        = {276--281},
  publisher    = {Taylor & Francis},
  series       = {Acta Oncologica},
  title        = {A population-based study on the first forty-eight breast cancer patients receiving trastuzumab (Herceptin (R)) on a named patient basis in Sweden},
  url          = {http://dx.doi.org/10.1080/02841860260088827},
  volume       = {41},
  year         = {2002},
}